From: The role of colchicine in the management of COVID-19: a Meta-analysis
Authors | Year of publication | Type of study | Study population | Participants (Colchicine/ Control) | Colchicine drug dose | Control | Outcomes |
---|---|---|---|---|---|---|---|
Deftereos et al. | 2020 | RCT | Hospitalized COVID-19 adult patients | 55/50 | Loading dose: 1.5 mg followed by 0.5 mg 60 minutes later. Maintenance dose: 0.5 mg twice daily until hospital discharge or for 21 days. | Standard treatment | Mortality, Mechanical Ventilation |
Tardif et al. | 2021 | RCT | Non-hospitalized COVID-19 adult patients | 2235/2253 | 0·5 mg twice per day for the first 3 days and then once per day for 27 days | Placebo | Mortality, Hospitalization, Mechanical Ventilation |
Lopes et al. | 2021 | RCT | Hospitalized COVID-19 adult patients | 36/36 | 0.5 mg 3 times daily for 5 days, then 0.5 mg twice daily for 5 days | Placebo | Mortality, ICU Admission, ICU length of stay |
RECOVERY Collaborative Group | 2021 | RCT | Hospitalized COVID-19 adult patients | 5610/5730 | 1 mg followed by 500 μg 12 hours later and then 500 μg twice a day for 10 days or until discharge | Standard care | Mortality |
Sandhu et al. | 2020 | NRCT | Hospitalized COVID-19 adult patients | 34/78 | 0.6 mg twice daily for 3 days and then 0.6 mg daily for 12 days | Standard care | Mortality, rate of intubation, rate of hospital discharge |
Mareev et al. | 2021 | NRCT | Hospitalized COVID-19 adult patients | 21/22 | 1 mg colchicine during the first 1–3 days followed by 0.5 mg/day | Placebo | Mortality, length of hospital stay. |
Brunetti et al. | 2020 | Cohort | Hospitalized COVID-19 adult patients | 33/33 | loading dose: 1.2 mg. maintenance dose: 0.6 mg twice daily | Standard care | Mortality, hospital discharge, clinical improvement |
Scarsi et al. | 2020 | Cohort | Hospitalized COVID-19 adult patients | 122/140 | colchicine 1 mg/day (reduced to 0.5 mg/day, if severe diarrhoea) | Standard care | survival |